{
    "clinical_study": {
        "@rank": "8390", 
        "arm_group": [
            {
                "arm_group_label": "EC-Doc", 
                "arm_group_type": "Experimental", 
                "description": "4 cycles epirubicin + docetaxel (90/600) i.v., q = 3 weeks, followed by 4 cycles docetaxel (100) i.v.,  q = 3 weeks"
            }, 
            {
                "arm_group_label": "CMF/CEF", 
                "arm_group_type": "Active Comparator", 
                "description": "6 cycles cyclophosphamide, methotrexate, 5-fluorouracil (CMF) (600/40/600) i.v., day 1 + 8, q = 4 weeks or 6 cycles cyclophosphamide, epirubicin, 5-fluorouracil (CEF) (500/100/500) i.v., day 1, q = 3 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Taxane-based adjuvant chemotherapy is standard in node-positive (N+) early breast cancer\n      (BC). The magnitude of benefit in intermediate-risk N+ early BC is still unclear. West\n      German Study Group and \"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie\" (WSG-AGO) EC-Doc is a\n      large trial evaluating modern sequential taxane-based chemotherapy in the subgroup with 1-3\n      involved lymph nodes (LN)."
        }, 
        "brief_title": "4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF", 
        "completion_date": {
            "#text": "August 2010", 
            "@type": "Actual"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female patients\n\n          -  Age 18-65 years\n\n          -  Eastern Cooperative Oncology Group (ECOG) status < 2\n\n          -  Surgery: R0-resection and >= 10 removed axillary lymph nodes\n\n          -  M0 by chest x-ray, bone scintigraphy and liver sonography\n\n        Exclusion Criteria:\n\n          -  Polyneuropathy\n\n          -  Creatinin (serum) > 1,4 mg/dl; Bilirubin (serum) > 2,0 mg/dl\n\n          -  Cardia dysfunction, ejection fraction < lower normal value of each institution\n\n          -  Hematopoeitic insufficiency: leucocytes < 3,5 G/l, thrombocytes < 100 G/l\n\n          -  second malignant neoplasia, except curatively treated basalioma of the skin\n\n          -  Surgery before more the six weeks (42 days)\n\n          -  Concurrent pregnancy; patients of childbearing potential must implement a highly\n             effective (less than 1% failure rate) non-hormonal contraceptive measures during the\n             study treatment\n\n          -  Breast feeding woman\n\n          -  Sequential breast cancer\n\n          -  Reasons indicating risk of poor compliance\n\n          -  Patients not able to consent"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2011", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02115204", 
            "org_study_id": "EC-Doc"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "EC-Doc", 
                    "CMF/CEF"
                ], 
                "intervention_name": "Epirubicin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "EC-Doc", 
                    "CMF/CEF"
                ], 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "EC-Doc", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CMF/CEF", 
                "intervention_name": "Methotrexate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CMF/CEF", 
                "intervention_name": "5-fluorouracil", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Fluorouracil", 
                "Methotrexate", 
                "Docetaxel", 
                "Epirubicin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Moenchengladbach", 
                    "country": "Germany", 
                    "zip": "41061"
                }, 
                "name": "Ev. Hospital Bethesda"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Adjuvant Chemotherapy of Breast Cancer: Sequential Chemotherapy vs. Standard Therapy. Prospective Randomised Comparison of 4 x Epirubicin and Cyclophosphamide (EC) --> 4 x Docetaxel (Doc) vs. 6 x CMF / CEF in Patients With 1 to 3 Positive Lymph Nodes", 
        "overall_official": {
            "affiliation": "Ev. Hospital Bethesda, Moenchengladbach", 
            "last_name": "Ulrike Nitz, Prof. Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Comparison of event-free survival", 
            "safety_issue": "Yes", 
            "time_frame": "60 months after end of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02115204"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Comparison of overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "60 months after end of treatment"
            }, 
            {
                "measure": "Comparison of toxicity (measured as number of adverse events)", 
                "safety_issue": "No", 
                "time_frame": "60 months after end of treatment"
            }, 
            {
                "measure": "Comparison of quality of life", 
                "time_frame": "60 months after end of treatment"
            }, 
            {
                "measure": "Comparison of cost effectiveness across the applied regimens in relation to event-free survival", 
                "time_frame": "60 months after end of treatment"
            }
        ], 
        "source": "West German Study Group", 
        "sponsors": {
            "collaborator": {
                "agency": "AGO Germany", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "West German Study Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2000", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}